Regeneron Pharmaceuticals, Inc. (REGN)
- Sector
- Health Care
- Industry
- Biotechnology
- Last price
- $778.36
- As of
Kresmion compiles this page from REGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
REGENERON PHARMACEUTICALS, INC. (REGN): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full REGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for REGN on one page. Preview it with sample data, then open it live with a free account.
Preview the REGN dossierActive signals for REGN
- highCONSENSUS_BUY
5 tracked funds increased REGN this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 79% of REGN (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased REGN this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 99% of REGN (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +486% to REGN (2026Q2)
FREE, NO ACCOUNT
Every signal on REGN, as it fires
You are seeing 5 of 60 signals recorded on REGN since 2026-05-02.
The five above landed across 2 days. The other 55 were recorded on 10 other days. 35 of the 60 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in REGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 75886F107 · 2026Q2 | $409.1M | 0.30% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 75886F107 · 2026Q2 | $103M | 0.04% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 75886F107 · 2026Q2 | $92.4M | 0.13% | , |
| CITADEL ADVISORS LLCCUSIP 75886F107 · 2026Q2 | $35.9M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 75886F107 · 2026Q2 | $32M | 0.13% | , |
| D. E. Shaw & Co., Inc.CUSIP 75886F107 · 2026Q2 | $24M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, REGN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
REGN against its peers
REGN's operating margin of 24.9% ranks in the 55th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | REGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 14.3B USD | 2.6B USD | 88 | 20 |
| Operating margin | 24.9% | 23.2% | 55 | 20 |
| Net margin | 31.4% | 16.7% | 75 | 21 |
| Return on equity | 14.4% | 14.7% | 48 | 21 |
| P / E | 18.8x | 29.1x | 13 | 11 |
| 1 year | 35.9% | 29.8% | 53 | 19 |
Peers (23): MRNA, NTRA, ARGX, VRTX, RVMD, ONC, BIIB, ALNY, GILD, AMGN, ROIV, RPRX, BNTX, UTHR, INCY, GMAB, INSM, ASND, EXEL, NBIX, SMMT, BBIO, HALO. Left out: CSLLY (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (REGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow REGN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to REGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.